Ashvattha Therapeutics reveals promising phase 2 results for migaldendranib, showcasing significant improvements in retinal ...

Financing will fund phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer’s Disease and ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

At ARVO 2025, in Salt Lake City, Utah, Ferhina Ali, MD, MPH, talked about her presentation on the early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macu ...